SCHEDULE 13G: Alphabet-Affiliated Entities Disclose 5.5% Passive Stake in Maze Therapeutics
Beneficial Ownership Disclosure
Alphabet Inc. and its affiliated investment entities, including GV, have disclosed a passive beneficial ownership of 5.5% of Maze Therapeutics, Inc.'s common stock as of March 31, 2025.
Summary
- Alphabet Inc., through its investment arms GV 2019, L.P. and GV 2023, L.P., along with their general partners and Alphabet subsidiaries (Alphabet Holdings LLC and XXVI Holdings Inc.), collectively reported beneficial ownership of 2,412,471 shares of Maze Therapeutics, Inc. common stock.
- This aggregate ownership represents 5.5% of Maze Therapeutics' outstanding common stock as of March 31, 2025.
- The filing indicates that GV 2019, L.P. directly owns 1,807,907 shares, accounting for 4.1% of the class.
- GV 2023, L.P. directly owns 604,564 shares, representing 1.4% of the class.
- All reporting persons hold shared voting and shared dispositive power over their respective beneficially owned shares.
- The total outstanding shares of Maze Therapeutics, Inc. used for calculation were 43,796,057 as of March 25, 2025, as reported by the Issuer in its Annual Report on Form 10-K for the period ended December 31, 2024.
Sentiment
Score: 7
Explanation: The disclosure of a significant passive stake by Alphabet's venture arm (GV) in Maze Therapeutics is generally a positive signal, indicating investor confidence and potentially attracting further attention to the company. While passive, it suggests a belief in the company's long-term value.
Positives
- The disclosure of a significant passive stake by Alphabet-affiliated entities (GV) may signal confidence in Maze Therapeutics, Inc.'s long-term prospects.
- The involvement of a prominent investor group like GV could potentially enhance Maze Therapeutics' visibility and credibility within the biotech and investment communities.
Negatives
- The filing is a passive investment disclosure and does not indicate any active strategic involvement or immediate plans for the company.
Risks
- The filing itself does not detail specific risks for Maze Therapeutics, Inc.; it is solely an ownership disclosure.
Future Outlook
NA
Industry Context
The investment by GV, Alphabet's venture capital arm, in Maze Therapeutics, a biotechnology company, aligns with broader industry trends of large tech companies and their investment vehicles diversifying into life sciences and healthcare, seeking opportunities in innovative therapeutic areas.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor like Alphabet (via GV) could be viewed positively, potentially increasing investor confidence and market interest in Maze Therapeutics' stock.
Key Dates
| Date | Description |
|---|---|
| 2024-12-31 | Period end date for Maze Therapeutics' Annual Report on Form 10-K, which reported 43,796,057 shares outstanding as of March 25, 2025. |
| 2025-03-25 | Date as of which Maze Therapeutics, Inc. reported 43,796,057 shares of common stock outstanding in its Annual Report for the period ended December 31, 2024. |
| 2025-03-31 | Date of event which required the filing of this Schedule 13G, indicating the beneficial ownership threshold was met or the reporting period ended. |
| 2025-05-09 | Date the Joint Filing Agreement and the Schedule 13G were signed and filed. |
Keywords
Maze Therapeutics, Alphabet Inc., GV, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology Investment, Venture Capital, Passive Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.